MedTrace Logo

Outcome of ADPKD With Octreotide LAR

NCT06193616 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2025-09-05

No results posted yet for this study

Summary

In this observational, retrospective study we will primarily aim at evaluating the independent role of baseline clinical and laboratory parameters, including TKV, in the prediction of long term chronic GFR decline and other clinical outcomes and, secondarily, the relationships between GFR and TKV changes over time, in a cohort of ADPKD patients with Stage IV CKD on chronic treatment with octreotide LAR and routinely monitored with serial GFR, TKV and clinical evaluations, at the outpatient clinic of the Nephrology Unit of the Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.

Conditions

  • Autosomal Dominant Polycystic Kidney

Interventions

DRUG

Octreotide

All consenting patients treated with octreotide LAR according to Determina AIFA n. 1264 del 3 August 2018 and fulfilling the selection criteria will be collected at prespecified time-points according to the routine visits scheduled for these patients and the periodic follow-up visits till dialysis initiation as described in the AIFA indication on GU Serie Generale n.5 del 08-01-2020.

Sponsors & Collaborators

  • Mario Negri Institute for Pharmacological Research

    lead OTHER

Principal Investigators

  • Giuseppe Remuzzi, MD · Istituto Di Ricerche Farmacologiche Mario Negri

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-12
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06193616 on ClinicalTrials.gov